Navigation Links
YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
Date:11/11/2009

pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Summary financial statements attached:

    YM BIOSCIENCES INC.
    Interim Consolidated Balance Sheets
    (Expressed in Canadian dollars,
     unless otherwise noted)

    -------------------------------------------------------------------------
                                                September 30,        June 30,
                                                        2009            2009
    -------------------------------------------------------------------------
                                                  (Unaudited)

    Assets

    Current assets:
      Cash                                     $  34,269,093   $   2,337,716
      Short-term deposits                          5,205,955      39,713,042
      Accounts receivable                            439,911         564,584
      Prepaid expenses                               231,488         352,850
      -----------------------------------------------------------------------
                                                  40,146,447      42,968,192

    Property and equipment                            84,187          96,876

    Intangible assets                             
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... ... Vieillard as Sales & Marketing Director. , With more than 25 years ... responsible for reinforcing Tronics’ business development activities worldwide. He brings to the company ...
(Date:7/30/2015)... --  Senomyx , Inc. (NASDAQ: SNMX ), a ... develop, and commercialize novel flavor ingredients for the food, ... for the second quarter 2015. "Moving ... track to achieve our commercial and financial goals," stated ... Company. "Since our last quarterly earnings report, our two ...
(Date:7/30/2015)... ... July 30, 2015 , ... As part of its 2015 growth plan and as a follow ... service business units, Whitehouse Laboratories is pleased to announce that it has begun construction ... Center of Excellence and will be strictly dedicated to basic USP 51, USP 61, and ...
(Date:7/29/2015)... July 29, 2015 US-Australian drug discovery company, ... confirmed it is committed to progressing its ground-breaking technology ... practicable and to ensure the Company delivers the best ... Iain Ross , said the Company currently had ... pre-clinical programs, discovery programs and academic partnerships and initiatives, ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... independent dermatology company, acquired by GSK in deal ... will have combined revenues of approximately $1.5 billion ... grow and diversify GSK,s business, providing immediate new ... plc (NYSE: GSK ) and Stiefel ...
... This release is available in German . ... Loligo vulgaris , is able to rapidly ,and efficiently ... used in the Tokyo subway attacks in 1995. A ... chemical reactions is ,necessary for efforts aiming to improve ...
... Keystone Symposia on Molecular and Cellular Biology will convene its ... 2009 at the Fairmont Empress Victoria in Victoria, British Columbia. ... within the speaker line-up.Andrew Fire of Stanford University ... 25 on "Adventures in the Small RNA-ome." On Monday morning, ...
Cached Biology Technology:GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business 2GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business 3GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business 4Structure of enzyme against chemical warfare agents determined 2Nobel Laureates to Speak at Keystone Symposia RNA Silencing Conference 2
(Date:7/31/2015)... , 31. Juli 2015 Die 10. internationale Konferenz ... BGI veranstaltet und findet vom 22. bis 25. ... , statt. Die Konferenz feiert ... Start 2006 ist die ICG weltweit zu einem ... Sie ist eines der dynamischsten, enthusiastischsten und angenehmsten ...
(Date:7/27/2015)... SAN JOSE, Calif. , July 27, 2015 ... leading developer of human interface solutions, today announced ... ClearPad ® touchscreen solution for its stylish ... controller for its proven reliability, low power and ... with a wet finger. Huawei designers also required ...
(Date:7/21/2015)... Sweden , July 21, 2015 Today, ... FPC1025. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... The U.S. Pharmacopeial (USP) Convention today announced results of ... Lot P Reference Standard tablets to two marketed drugs. ... Lot P tablets than in the marketed tablets. Dissolution ... role in drug manufacturing because it indicates whether a ...
... Can diseases such as Alzheimers, obesity and diabetes be ... M.D., the Helene B. Roberson Professor of Pediatrics and ... Medicine, researching whether diseases that strike adults are already ... may enable physicians to one day address and prevent ...
... release is available in Spanish . ... the chemical composition of the rock, etc give rise ... paint coats detachment, dust accumulation, etc. , The treatments ... have been directed, almost exclusively, to preserve the beauty ...
Cached Biology News:Prednisone tablets less variable than marketed drugs 2Leading pediatrician addresses the future of children's health 2New mineralogical techniques contribute to prevent national heritage damage 2New mineralogical techniques contribute to prevent national heritage damage 3
... The versatile ST-195 allows real-time observations of ... This instrument has 64 different strain parameters ... incubator. The thin silicon strain chamber used ... microscopes and fluorescence microscopy. ST-195 can be ...
... Control and regulate cell stretching or compression ... microscope stage. Computer controlled so you can ... the strain to produce 64 unique strain ... then the ST-150. Both models are compatible ...
... reagents package is used for determining protein concentration ... The RC DC protein assay is a colorimetric ... standard assays: 250 ml RC reagent I, 250 ... tartrate solution, 2 L dilute Folin reagent, and ...
... used in conjunction with the EasyCount System to ... The ViaSure Staining Reagent uses a mixture of ... Ethidium Bromide to identify live and dead cells, ... Slide 6 Multi-well Slide provides the ability ...
Biology Products: